At the news
? BULLISHIMPACT 7/10 6-K filed Aug 31, 2026 at 06:03 ET
HUTCHMED announces positive Phase III SANOVO trial results showing ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) significantly improves progression-free survival vs TAGRISSO alone in first-line MET-overexpressing EGFR-mutated NSCLC in China. The combination also demonstrated encouraging overall survival benefit. This expands the clinical value of the all-oral combination into the first-line setting, building on prior SACHI and SAFFRON trials. The data will be submitted to regulatory authorities for label expansion in China.
- SANOVO Phase III met primary endpoint: statistically significant and clinically meaningful PFS improvement vs TAGRISSO alone in both high MET and ITT populations
- Encouraging OS benefit observed as secondary endpoint; trial continues follow-up
- Safety profile consistent with known profiles of each medicine; no new safety findings
- 326 treatment-naïve patients randomized 1:1 to ORPATHYS+TAGRISSO vs TAGRISSO+placebo
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access